Adagio Medical Holdings Inc (ADGM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$0.59-2.40%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Cash from operations improves toward break-even: OCF TTM -13.1M vs trip -6.0M.
Adagio is cutting losses and improving cash flow. Operating loss fell from $7.4M to $5.2M. Cash from operations improved by $3.1M. The FDA application for a new product is a strong step forward.
Adagio is still losing money and faces Nasdaq delisting risk. Losses and EPS improvements are small. The stock is down 62.5% from its high. Regulatory issues may hurt investor confidence.
The market is selling off sharply, reflecting high risk and regulatory concerns. There is no clear consensus revenue growth or fair value priced in. Our view sees some progress but high uncertainty.
Breaks if: Cash from operations worsens beyond negative $6 million
Focus on reducing operating losses and improving cash flow to stabilize financial condition over multiple quarters.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
ADGM represents a speculative growth investment, as it is in the development stage with a focus on advancing its ULTA technology. The current thesis state is cautious, given its recent financial performance and volatility in management execution.
The market appears to be pricing in a high level of risk, as indicated by its premium valuation compared to peers. There is a low fragility tier, suggesting that while the stock is under pressure, it has not yet reached a critical point.
Management is on track with key priorities such as achieving FDA approval and demonstrating the clinical effectiveness of its ULTA platform. However, the company continues to experience negative cash flow, indicating challenges in managing its financial position.
The thesis hinges on several factors, including the outcome of upcoming earnings guidance, broader economic conditions affecting the healthcare sector, and the performance of sector leaders that could influence ADGM's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Failure to regain Nasdaq compliance within 2 quarters
Breaks if: Net loss rises above $8 million or EPS falls below -$0.5
Breaks if: Operating loss worsens beyond negative $7 million
Focus on reducing operating losses and improving cash flow to stabilize financial condition over multiple quarters.
In the next 1 to 3 years, ADGM's performance will depend on its ability to navigate regulatory challenges and improve its financial health. Not investment advice.